

(FILE 'HOME' ENTERED AT 21:52:44 ON 31 MAY 2003)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
AT 21:52:52 ON 31 MAY 2003

L1 292 S TRANSGEN? (L) (SCURFY OR SF OR FKHSF)
L2 105 DUP REM L1 (187 DUPLICATES REMOVED)
L3 89 S L2 AND TRANSGENIC
L4 43 S L3 AND PY<=1998
L5 43 FOCUS L4 1-
L6 3 S L5 AND (SCURFY (L) TRANSGENIC)
L7 17 S SCURFY (L) TRANSGENIC
L8 6 DUP REM L7 (11 DUPLICATES REMOVED)
L9 6 SORT L8 PY

=> d an ti so au ab pi l9 4

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2000:133832 CAPLUS

DN 132:190512

TI Gene causing the mouse scurfy phenotype and its human ortholog

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

IN Brunkow, Mary E.; Jeffery, Eric W.; Hjerrild, Kathryn A.; Ramsdell, Fred
AB The present invention relates generally to the discovery of novel genes
which, when mutated, results in a profound lymphoproliferative disorder.
In particular, a mutant mouse designated Scurfy was used to identify the
gene responsible for this disorder through backcross anal., phys. mapping,
and large-scale sequencing. Isolated nucleic acid mols. are provided
which encode Fkhsf, as well as mutant forms, which belongs to a family of
related genes, all contg. a winged-helix DNA binding domain. The mouse
Fkhsf gene spans .apprx.14 kb and contains 11 coding exons; the cDNA spans
a coding region of 1287 bp and encodes a protein of 429 amino acids. The
human ortholog to mouse Fkhsf cDNA is also provided. Also provided are
expression vectors suitable for expressing such nucleic acid mols., and
host cells contg. such expression vectors. Utilizing assays based upon
the nucleic acid sequences disclosed herein (as well as mutant forms
thereof), numerous mols. may be identified which modulate the immune
system.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000009693	A2	20000224	WO 1999-US18407	19990811
WO 2000009693	A3	20000615		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2339409	AA	20000224	CA 1999-2339409	19990811
AU 9955594	A1	20000306	AU 1999-55594	19990811
EP 1105479	A2	20010613	EP 1999-942154	19990811
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6414129	B1	20020702	US 1999-372668	19990811
JP 2002538764	T2	20021119	JP 2000-565128	19990811
US 2002168736	A1	20021114	US 2002-115195	20020402

(FILE 'HOME' ENTERED AT 21:52:44 ON 31 MAY 2003)

FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
AT 21:52:52 ON 31 MAY 2003

L1 292 S TRANSGEN? (L) (SCURFY OR SF OR FKHSF)
L2 105 DUP REM L1 (187 DUPLICATES REMOVED)
L3 89 S L2 AND TRANSGENIC
L4 43 S L3 AND PY<=1998
L5 43 FOCUS L4 1-
L6 3 S L5 AND (SCURFY (L) TRANSGENIC)

=> d an ti so au ab l6 1-3

L6 ANSWER 1 OF 3 MEDLINE
AN 96152740 MEDLINE
TI Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes.
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1996 Jan) 26 (1) 161-5.
Journal code: 1273201. ISSN: 0014-2980.
AU Kanangat S; Blair P; Reddy R; Deheshia M; Godfrey V; Rouse B T; Wilkinson E
AB The murine X-linked lymphoproliferative disease **scurfy** is similar to the Wiskott-Aldrich syndrome in humans. Disease in **scurfy** (sf) mice is mediated by CD4+ T cells. Based on similarities in **scurfy** mice and **transgenic** mice that overexpress specific cytokine genes, we evaluated the expression of cytokines in the lesions of **sf** mice by Northern blotting, quantitative reverse-transcription polymerase chain reaction (RT-PCR) and by hybridization in situ. Overall, the phenotypic characteristics of **scurfy** disease correlated well with increased interleukin (IL)-4 (lymphadenopathy), IL-6 (B cell proliferation, hypergammaglobulinemia), IL-7 (dermal inflammatory cell infiltration), and high levels of tumor necrosis factor-alpha (wasting).

L6 ANSWER 2 OF 3 MEDLINE
AN 95015867 MEDLINE
TI CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse.
SO JOURNAL OF IMMUNOLOGY, (1994 Oct 15) 153 (8) 3764-74.
Journal code: 2985117R. ISSN: 0022-1767.
AU Blair P J; Bultman S J; Haas J C; Rouse B T; Wilkinson J E; Godfrey V L
AB Mice hemizygous for the X-linked mutation, **scurfy** (sf), exhibit a fatal lymphoreticular disease that is mediated by T lymphocytes. To evaluate the respective roles of CD4 or CD8 single positive T cells in **scurfy** disease, neonates were treated with mAbs directed against the CD4 or CD8 molecules. Whereas mice treated with an anti-CD8 Ab developed lesions and succumbed to disease at the same time (17 days) as their untreated **scurfy** littermates, mice treated with an anti-CD4 Ab lived up to 11 wk before developing **scurfy** disease. To insure a more complete elimination of the T cell subsets, the **scurfy** mutation was bred onto beta 2-microglobulin (beta 2m)-deficient (CD8-less) and CD4-deficient **transgenic** mouse lines. Whereas there was little moderation of disease in beta 2m-deficient **scurfy** mice, CD4-deficient **scurfy** mice had markedly decreased **scurfy** lesions and a prolonged life span, similar to that of anti-CD4-treated **sf/Y** mice. Additionally, **scurfy** disease was transplanted into H-2-compatible nude mice through the adoptive transfer of CD4+CD8- T cells, but not CD4-CD8+ T cells. Flow-cytometric analysis revealed that **sf/Y** mice have an increased percentage of activated CD4+ T cells in their lymph nodes. In addition, there is an increase in the in vitro production of cytokines in the cultured splenocytes of CD8-less, but not CD4-less, **scurfy** mice. These data suggest that CD4+ T cells are critical mediators of disease in the **scurfy** mouse.

L Number	Hits	Search Text	DB	Time stamp
1	3	Ramsdell-fred.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
7	30012	transgenic	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
16	1609	800/\$2.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
13	1	(US-20020016974-\$).did. or	US-PGPUB;	2003/05/31 21:47
22	1	(WO-200009693-\$).did.	DERWENT	2003/05/31 21:47
		800/\$2.ccls. and scurfy	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
28	21	transgenic SAME (scurfy or sf or FKhsf)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
34	21	scurfy or fkhsf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
40	8	Brunkow-mary\$3.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/31 21:47
46	1	(US-6414129-\$).did. or (US-20020016974-\$).did. or (WO-200009693-\$).did.	USPAT; US-PGPUB; DERWENT	2003/05/31 21:47